Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biotechnology company developing intranasal foralumab, the only fully human anti-CD3 monoclonal antibody in clinical development, for neuroinflammatory and neurodegenerative diseases including MS, Alzheimer's, MSA, and ALS.
- Company typePublic
- Founded2013
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Tiziana Life Sciences does
Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company developing intranasal immunomodulation therapies for neuroinflammatory and neurodegenerative diseases, incorporated in Bermuda with operational offices in Boston and London. The company's lead and only clinically advanced asset is intranasal foralumab (TZLS-401), the only fully human anti-CD3 monoclonal antibody in clinical development, which it positions as a non-invasive alternative to intravenous anti-CD3 delivery, stimulating T regulatory cells to dampen microglial activation and reduce neuroinflammation. The pipeline is anchored by Phase 2 programs in non-active Secondary Progressive Multiple Sclerosis (48-patient INFORM-MS trial with enrollment completed May 2026), Multiple System Atrophy (Phase 2a TILS-025 trial), and mild-to-moderate Alzheimer's Disease, supplemented by Expanded Access Programs, an ALS program accepted into the Healey MyMatch Program, and preclinical work in Long COVID and intracerebral hemorrhage.
The company generates no commercial revenue and operates as a research-driven biotech, conducting multicenter trials through partnerships with Brigham and Women's Hospital and Mass General Brigham under the scientific leadership of Dr. Howard Weiner, and drawing on NIH and ALS Association grant funding alongside periodic registered direct equity offerings. Insider ownership is concentrated, with Executive Chairman Gabriele Cerrone holding approximately 34.89% of issued shares and CEO Ivor Elrifi materially participating in recent raises. Patent protection on the foralumab composition, formulation, and indication space extends to 2040. Revenue mechanics are pre-commercial: future value creation depends on Phase 2/3 readouts (MS topline expected late Q3/early Q4 2026), potential licensing deals, and the planned spin-out of the second asset TZLS-501 (anti-IL-6 receptor mAb) into a separate publicly traded entity.
Tiziana Life Sciences firmographics
Firmographics- Name
- Tiziana Life Sciences
- Legal name
- Tiziana Life Sciences plc
- Website
- https://tizianalifesciences.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Tiziana Life Sciences is a clinical-stage biotechnology company developing intranasal foralumab, the only fully human anti-CD3 monoclonal antibody in clinical development, for neuroinflammatory and neurodegenerative diseases including MS, Alzheimer's, MSA, and ALS.
- Ownership category
- akta.pro rank
Tiziana Life Sciences industry classification
Industry- Product category
- Clinical-stage Biopharmaceuticals (Neuroimmunology)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)
Keywords
Where Tiziana Life Sciences is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Tiziana Life Sciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Biopharmaceutical Development: Pre-revenue clinical-stage biopharmaceutical company. Developing breakthrough therapies for neuroinflammatory and neurodegenerative diseases. No commercial products yet - all candidates are in clinical development stages.
- Potential Future Licensing/Spinout - TZLS-501: Company announced plans to spin out its anti-IL-6 receptor monoclonal antibody TZLS-501 into a separate publicly traded company, citing increased industry interest exemplified by Novartis' recent acquisition of Tourmaline Bio. This represents potential future licensing or spinout revenue stream.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Tiziana Life Sciences product offering
Product offeringCore offering
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing intranasal foralumab (TZLS-401), the only fully human anti-CD3 monoclonal antibody in clinical development, for neuroinflammatory and neurodegenerative diseases including non-active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's Disease, and ALS. The company also develops an anti-IL-6 receptor monoclonal antibody (TZLS-501) for lung diseases and is exploring milciclib in oncology.
Differentiator
Problem solved
Functional benefit
Products and services
- Intranasal Foralumab (TZLS-401) Intranasal Foralumab (TZLS-401) is the only fully human anti-CD3 monoclonal antibody in clinical development, delivered via Tiziana's proprietary intranasal platform to stimulate T regulatory cells and reduce neuroinflammation. It is being developed for non-active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's Disease, ALS, Long COVID, and other neuroinflammatory indications. Patents covering composition, formulation, and indications are protected through 2040.
- Anti-IL-6 Receptor Monoclonal Antibody (TZLS-501) Anti-IL-6 Receptor Monoclonal Antibody (TZLS-501) is a fully human monoclonal antibody targeting the receptor for IL-6, being developed as a potential treatment for lung diseases and being positioned for spinout into a separate publicly traded company.
- Milciclib Milciclib is being explored by Tiziana in a combination study with gemcitabine in NSCLC subjects with associated pan-KRAS-positive mutations.
Quantifiable outcome
- 83% of patients (5 of 6) showed reduction in microglial PET signal after 3 and 6 months of treatment
- +4 more outcomes
Companies that use Tiziana Life Sciences
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles3 records
Tiziana Life Sciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Tiziana Life Sciences partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered supporting and core.
- Yale UniversitysupportingCollaborated with Yale University researchers on preclinical data for Long COVID study. Research demonstrated that intranasal foralumab reduced neuroinflammation and improved cognitive function in mouse model of Long COVID.
- Brigham and Women's HospitalcorePrimary research partner conducting multiple clinical trials including Phase 2a na-SPMS trial (INFORM-MS), Phase 2 MSA trial (TILS-025), and Expanded Access Programs for Alzheimer's disease. Led by Dr. Howard Weiner and Dr. Tanuja Chitnis. Founded by researchers with decades of experience in neuroinflammatory diseases.
- Mass General BrighamcoreMajor healthcare system overseeing clinical trial sites. Phase 2 ALS trial accepted into Healey ALS MyMatch Program at Mass General Brigham. Multiple hospitals within network serve as clinical trial sites.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Tiziana Life Sciences competitors and assessment
Company assessmentDirect peers
- Anavex Life Sciences: Small-cap clinical-stage biotech focused on neurodegenerative diseases including Alzheimer's and Rett syndrome. Directly comparable to Tiziana in size, stage, indication overlap, and pre-revenue clinical development model.
- BioXcel Therapeutics: Clinical-stage biotech developing neuroinflammation and immunology therapies. Comparable in immunomodulation mechanism, small-cap clinical structure, and CNS indication focus.
- Prothena Corporation: Clinical-stage biotech developing monoclonal antibody therapies for neurodegenerative diseases including Parkinson's and Alzheimer's. Comparable in biologics platform, neuro focus, and pipeline-driven small-cap profile.
- Sage Therapeutics: CNS-focused biotech developing therapies for neurological disorders including multiple sclerosis. Comparable in neuro-focused pipeline, monoclonal antibody/biologics development, and small-cap clinical-stage structure.
- Voyager Therapeutics: Clinical-stage biotech developing gene therapy and antibody therapeutics for neurological diseases including Alzheimer's and ALS. Comparable in CNS indication focus and clinical-stage development model.
- Cassava Sciences: Clinical-stage biotech developing simufilam for Alzheimer's disease. Closely comparable in market cap, single-asset narrative, Phase 2/3 readout catalysts, and small-cap neurodegenerative focus.
- Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's, Alzheimer's, and ALS. Comparable in neuroimmunology pipeline, biologics approach, and multi-indication strategy.
- AC Immune SA: Clinical-stage biotech developing therapeutics and diagnostics for neurodegenerative diseases. Comparable in anti-amyloid and neuroinflammation focus, biologics platform, and partnership-driven clinical development model.
- Atara Biotherapeutics: Clinical-stage biotech developing T-cell and monoclonal antibody immunotherapies. Comparable in biologics platform, immunomodulation mechanism, and MS/neuro indications.
- Annexon, Inc. Clinical-stage biotech developing complement-mediated neuroinflammation therapeutics for neurodegenerative diseases. Directly comparable in neuroinflammatory mechanism, Phase 2 stage, and indication overlap (MS, ALS, Alzheimer's).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Tiziana Life Sciences social profiles
Digital presenceTiziana Life Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tiziana Life Sciences leadership team
Management profileNumber of profiles
Profiles5 records
Tiziana Life Sciences funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tiziana Life Sciences M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tiziana Life Sciences
What does Tiziana Life Sciences do?
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing intranasal foralumab (TZLS-401), the only fully human anti-CD3 monoclonal antibody in clinical development, for neuroinflammatory and neurodegenerative diseases including non-active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's Disease, and ALS. The company also develops an anti-IL-6 receptor monoclonal antibody (TZLS-501) for lung diseases and is exploring milciclib in oncology.
Is Tiziana Life Sciences a public or private company?
Tiziana Life Sciences is a public company. It is classified as public and is currently operating.
When was Tiziana Life Sciences founded?
Tiziana Life Sciences was founded in 2013. It employs 11 to 50 people.
Where is Tiziana Life Sciences based?
Tiziana Life Sciences is headquartered in London, United Kingdom, in the Europe region.
How does Tiziana Life Sciences make money?
Two revenue lines are on record. Biopharmaceutical Development is the primary driver. The others are potential Future Licensing/Spinout - TZLS-501.
Who are Tiziana Life Sciences's main competitors?
Direct peers on record are Anavex Life Sciences, BioXcel Therapeutics, Prothena Corporation, Sage Therapeutics, Voyager Therapeutics, Cassava Sciences, Denali Therapeutics, AC Immune SA, Atara Biotherapeutics and Annexon, Inc..
Does Tiziana Life Sciences have an API?
No public API is recorded for Tiziana Life Sciences.
What industry is Tiziana Life Sciences in?
Tiziana Life Sciences's product category is Clinical-stage Biopharmaceuticals (Neuroimmunology). Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.